Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Atrogi AB is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 actions are being handled by 3 distinct examiners, yet all are concentrated within a single distinct art unit. This indicates that while the company faces multiple reviewers, the subject matter remains situated within a specific technical group. This concentration within a single art unit can lead to more consistent prior art applications but requires managing the perspectives of different individuals.
The busiest examiner, CLARK, AMY LYNN, is responsible for 1 pending office action. Given that the busiest examiner pending count is 1 and there are multiple examiners, the workload is spread across the examination staff. This distribution minimizes the impact of any single examiner's specific allowance rates on the overall portfolio. It also suggests that the company's pending office actions are receiving independent reviews from different sets of eyes within the same technical field.
Practitioners should note that having multiple examiners within a single art unit provides an opportunity to see how different individuals in the same group interpret the company's biotechnology claims. The split of a single pending office action per examiner means that no individual has more influence than another. This balanced workload is a key feature of Atrogi AB's current prosecution profile in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARK, AMY LYNN | 1 | 39.1% | +31.2% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | — |
| 18678103 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717134 | CRYSTALLINE FORM OF (R)-2-(TERT-BUTYLAMINO)-1-(5-FLUOROPYRIDIN-3-YL)-ETHAN-1-OL HEMI-TARTRATE SALT FOR THE TREATMENT OF HYPERGLYCEMIA AND DIABETES 2 | CLARK, AMY LYNN | — | §103§112 | Non-Final OA | — | Pending | Jun 06, 2024 |
| 18678103 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | BRAUN, MADELINE E | — | §103§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18693573 | SUBSTITUTED HYDROXYMETHYL PYRROLIDINES AND MEDICAL USES THEREOF | SHTERENGARTS, SAMANTHA L | 1623 | §102 | Non-Final OA | — | Pending | Mar 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial